Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

Summer 2015

The Pathology of Heart Failure
Kevin Ahman
Otterbein University, kevin.ahman@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Cardiovascular Diseases Commons, Medical Pathology Commons, and the Nursing
Commons

Recommended Citation
Ahman, Kevin, "The Pathology of Heart Failure" (2015). Nursing Student Class Projects (Formerly MSN).
88.
https://digitalcommons.otterbein.edu/stu_msn/88

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

The Pathology of Heart Failure
Kevin Ahman RN, BSN, CCRN
Otterbein University, Westerville, Ohio
Introduction
The topic I have chosen to research is heart
failure. I have chosen this topic because I
have treated many patients in the ICU with
this condition, and find it an interesting
pathology. Heart failure affects a significant
portion of the patient population, and the
rates are increasing. 5.1 million Americans
≥20 years of age have heart failure,
projections show that by 2030, the
prevalence of HF will increase 25% from
2013 estimates. At 40 years of age, the
lifetime risk of developing HF for both men
and women is 1 in 5. At 80 years of age,
remaining lifetime risk for development of
new HF remains at 20% for men and women,
even in the face of a much shorter life
expectancy. While patients are now living
longer after initial diagnosis, about half of
the patients diagnosed die within five years.
Projections from the American Heart
Association show in 15 years, the total cost
of HF will increase almost 120% to $70 billion
from the current estimated total cost of $32
billion.

The specific ECG abnormality may be used
to guide treatment of HF. The
echocardiogram provides immediate
information on chamber volumes,
ventricular systolic and diastolic function,
wall thickness, and valve function. The
echocardiogram is central not only in the
diagnosis of heart failure, but also in the
identification of which specific type of
heart failure. Findings and their
corresponding abnormalities and
implications can be seen in the table below

adrenergic receptors, with the beta 1, beta
2, and alpha 1 receptors having the greatest
affect on cardiac performance.

Alpha affects
Alpha1-ARs heavily populate major arteries
(including the aorta,

Signs and Symptoms
The symptoms of heart failure can be divided
into two categories; typical and less typical.
Typical symptoms include shortness of
breath, orthopnea, paroxysmal nocturnal
dyspnea, decreased activity tolerance,
fatigue/tiredness, and ankle swelling. Less
typical symptoms include wheezing,
nocturnal cough, weight gain(more than 2 kg
in a week), weight loss(in advanced heart
failure), loss of appetite, confusion more
common in elderly), depression, palpitations,
and syncope.
Signs of heart failure can also be divided into
two categories; specific and less specific.
Specific signs include elevated jugular
pressure, hepato-jugular reflux, a third heart
sound(gallop), laterally displaced apical
impulse, and cardiac murmur. Less specific
signs include sacral or scrotal edema,
tachycardia, irregular pulse, tachypnea,
hepatomegaly, ascites, and cachexia.
the echocardiogram and electrocardiogram
(ECG) are the most useful tests in patients
with suspected HF. A variety of ECG findings
may occur for a patient in heart failure, and
no sole specific abnormality is indicative of
heart failure. However, less than 2% of
patients with heart failure will have a normal
ECG. This means that heart failure should at
least be considered as a diagnosis in patients
with any ECG abnormalities.

Underlying Pathology
Heart failure is a disease that results from
the body compensating for a drop in
cardiac output or blood pressure.
Compensatory mechanisms help maintain
cardiac output(increased contractility) and
BP(vasoconstriction). However, these
compensatory changes over months and
years can eventually worsen cardiac
function. Any phenomenon that can cause
impaired cardiac output or low blood
pressure can therefore be a cause of
heart failure, some examples include
cardiac structural abnormalities, MIs,
HTN, diabetes, and respiratory diseases.
Sympathetic Nervous System – The
Neurohumoral Response
The hypothalamus begins the response to
suboptimal cardiac output or BP. It begins
the process by signaling for the adrenal
glands to release epinephrine (EPI), and
for noradrenergic neurons to release
norepinephrine(NE). EPI and NE target

pulmonary arteries, mesenteric vessels,
and coronary arteries) and activation of
these receptors is a major contributor to
the regulation of blood flow because
they trigger vasoconstriction, resulting in
increased cardiac output.
Beta affects
Activation of beta1- and beta2-ARs is the
most powerful physiologic mechanism to
acutely increase cardiac performance.
Beta 1-ARs activate Gs proteins whereas
beta 2-ARs use both Gs and Gi proteins.
Gs signaling acts as a “receptoraccelerator,” and Gi signaling as a
“receptor-brake”. Gs signaling stimulates
the effector enzyme, adenyl cyclase,
resulting in dissociation of adenosine
triphosphate (ATP) into the second
messenger(cAMP), which in turn binds to
cAMP-dependent protein kinase A.
Targets of protein kinase A-induced
phosphorylations in the AR signaling
pathway are:
1) the L-type calcium channels and
ryanodine receptors, causing an increase
in calcium entry into the cell.

2) the hyperpolarization-activated cyclic
nucleotide-gated channels, which
generate the hyperpolarizationactivated cation inward current,
stimulating pacemaker cells of the heart
to increase the heart rate.
3) phospholamban, a modulator of the
sarcoplasmic reticulum associated ATPdependent calcium pump, which
increases calcium reuptake by the
sarcoplasmic reticulum, accelerating
cardiac relaxation.
4) troponin I and myosin binding
protein-C, which reduce myofilament
sensitivity to calcium, accelerating the
relaxation of myofilaments.
5) phospholemman, a subunit of
Na+/K+-ATPase, relieving its inhibitory
influence and resulting in the
stimulation of the sodium pump.
These affects combine to increase heart
rate and contractility.
Renin-Angiotensin-Aldosterone System
The RAAS plays an important role in
increasing vascular volume and vascular
resistance. RAAS is activated by beta 1, low
BP, or low sodium in the kidneys. When
renin is released into the blood, it acts
upon a circulating substrate,
angiotensinogen, that undergoes
proteolytic cleavage to form angiotensin I.
Vascular endothelium, particularly in the
lungs, has angiotensin converting enzyme
(ACE), that cleaves off two amino acids to
form the octapeptide, angiotensin II (AII),
although many other tissues in the body
(heart, brain, vascular) also can form AII.
Angiotensin II has the following affects:
-Arterial constriction, thereby increasing
systemic vascular resistance and arterial
pressure
-Stimulates sodium transport
(reabsorption) in renal tubules, increasing
sodium and water retention
-Acts on the adrenal cortex to release
aldosterone, which in turn acts on the
kidneys to increase sodium and fluid
retention
-Stimulates the release of vasopressin
(antidiuretic hormone, ADH) from the
posterior pituitary, which increases fluid
retention by the kidneys
-Stimulates thirst
-Facilitates norepinephrine release from
sympathetic nerve endings and inhibits
norepinephrine re-uptake by nerve
endings, thereby enhancing sympathetic
adrenergic function

Remodeling
Once the above phenomenon have taken
place, the remodeling process results, which
is what puts a patient into heart failure.
Although an exact picture of all the
pathways and cells involved in remodeling is
still unclear, the following scenario has been
proposed at a molecular level. As myocytes
stretch, local norepinephrine activity and
angiotensin and endothelin release are
increased. These changes stimulate
expression of altered proteins and myocyte
hypertrophy. The end result is further
deterioration in cardiac performance and
increased neurohormonal activation. In
addition, increased activation of
aldosterone and cytokines may also
stimulate collagen synthesis, thus leading to
fibrosis and remodeling of the extracellular
matrix. The heart becomes enlarged to the
point that it does not pump blood
effectively, and signs and symptoms of
heart failure begin.
Right Sided vs. Left Sided Failure
While much of the molecular process is the
same for right heart failure as it is for left
heart failure, the affects are different.
Instead of fluid backing up into the lungs as
it does with left sided failure, fluid backs up
into the venous system, causing swelling in
the periphery, typically in the lower
extremities.

Systolic vs. Diastolic Failure
Once the diagnosis of heart failure has been
made, the diagnosis may be classified as
systolic or diastolic failure. This
differentiation is primarily made using the
left ventricular ejection fraction(LVEF),
revealed by an echocardiogram. A reduced
LVEF is indicative of systolic heart failure,
while a normal result indicates the failure is
diastolic. The neurohormonal process is
similar for both types of failure, the
difference originates from the remodeling
process.
In systolic heart failure(SHF), the
remodeling process has resulted in a larger
left ventricle and larger left ventricular
cavity, but the wall thickness is decreased
or unchanged.
The heart wall does not have enough muscle
mass to overcome the increased amount of
blood in the ventricle, so a less than optimal
amount of blood is ejected. In diastolic heart
failure(DHF), the remodeling process has
resulted in an increased wall thickness, but
the size of the left ventricular cavity has not
increased, or has decreased. The ventricular
contraction ejects enough blood to result in a
normal LVEF, but since the volume of blood
in the ventricle before the contraction was
lower than normal, ejecting a normal
percentage of it is still inadequate.

.

Nursing Implications
Individuals diagnosed with heart failure
may be treated medically and with lifestyle
modifications. To avoid fluid overload, salt
intake should be restricted to 2-3g sodium
diets. Fluid restriction is also
recommended, and patients should weigh
themselves frequently to monitor their
status. Exercise should be encouraged.
Medical management includes the use of
diuretics to decrease fluid overload,
nitrates to reduce vascular resistance, and
beta blockers to suppress sympathetic
stimulation of heart rate, contractility, and
vasoconstriction. ACE inhibitors may be
prescribed to interrupt the reninangiotensin-aldosterone system’s affects.
Treatments of chronic heart failure do not
cure the disease, but slow its progression
and make symptoms more manageable.
Patients in acute heart failure will need
emergent intervention, including
administration of nitrates and diuretics as
appropriate with BP. Inotropic agents are
generally not recommended unless the
patient is in cardiogenic shock, because
inotropic drugs increase the workload of
the heart. If cardiac output is severely
compromised, inotropic meds may be
considered. Dobutamine is the inotrope of
choice for increasing cardiac output, blood
pressure, and peripheral circulation. In the
patient with heart failure that has produced
pulmonary edema, CPAP may be
considered

Conclusions
Rates of heart failure are increasing.
Understanding the pathology and
progression of the disease can help
healthcare providers assist patients in their
management of heart failure. Patient
education and adherence to treatment plans
is very important in successfully managing
the disease, and improving quality of life.
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